The groundbreaking “SUNLIGHTTrial” recently highlighted the potential of the combined treatment of Trifluridine–Tipiracil (FTD–TPI) and Bevacizumab in extending the lifespan of patients with advanced colorectal cancer. The promising phase 3 study builds on prior research suggesting the efficacy of FTD–TPI in these cases, and points to the enhanced potential of FTD–TPI when used in combination […]
Tag: bevacizumab
KEYNOTE-826 Trial Summary: Pembrolizumab in Metastatic Cervical Cancer
2021 KEYNOTE-826 TRIAL Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer double-blind, phase 3, randomized controlled trial Objective: To assess whether adding pembrolizumab to platinum-based chemotherapy with or without bevacizumab would improve efficacy as compared with chemotherapy with or without bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer 617 patients Participants 18 […]